ERN1 and triple-negative breast carcinoma: A recent paper by Logue et al. [78] reported that the common chemotherapeutic agent paclitaxel enhanced levels of cytokines such as IL-8 and IL-6 in an IRE1-associated manner in triple negative breast cancer cells, and they were reduced upon IRE1 RNase inhibition [78].